SCHEMBL558515

SCHEMBL558515

Nc1nnc2ccccn12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.55
ALDH1A1 P00352 4/20 0.55
RET P07949 2/20 0.53
KDR P35968 2/20 0.53
ALK Q9UM73 2/20 0.53
PIM1 P11309 1/20 0.53
FGFR1 P11362 1/20 0.53
FLT1 P17948 1/20 0.53
FLT3 P36888 1/20 0.53
PIM3 Q86V86 1/20 0.53
HSD17B10 Q99714 3/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 3/20 0.46
NPC1 O15118 3/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
LTK P29376 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1186616 0.98 KDM4E (0.53) KDM4EALDH1A1RETKDRALK
SCHEMBL11490669 0.74 KDM4E (0.57) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL7698945 0.73 KDM4E (0.56) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL1450341 0.73 KDM4E (0.55) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL1450345 0.73 KDM4E (0.55) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL20363016 0.73 KDM4E (0.55) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL253753 0.73 KDM4E (0.55) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL16402570 0.73 KDM4E (0.56) KDM4EALDH1A1FLT3HSD17B10KMT2A
SCHEMBL10809600 0.73 KDM4E (0.55) KDM4EALDH1A1HSD17B10KMT2AHPGD
SCHEMBL14759162 0.72 KDM4E (0.71) KDM4EALDH1A1HSD17B10KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116217571-B Method for preparing medicine building block 1,2, 4-triazolo [4,3-A ] pyridine-3-amine 上海锐谱医药科技有限公司 2024-11-15 CN claimed
CN-116217571-A Method for preparing medicine building block 1,2, 4-triazolo [4,3-A ] pyridine-3-amine 上海锐谱医药科技有限公司 2023-06-06 CN claimed
US-20250122182-A1 MYST Inhibitors Isosterix, Inc. 2025-04-17 US disclosed
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2025-02-13 US disclosed
EP-4499609-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2025-02-05 EP disclosed
CN-119301096-A Inhibitors of MYST family lysine acetyltransferase 伊索斯泰里克斯公司 2025-01-10 CN disclosed
US-12187732-B2 Inhibitors of the myst family of lysine acetyl transferases Isosterix, Inc. (US) 2025-01-07 US disclosed
CN-116217571-B Method for preparing medicine building block 1,2, 4-triazolo [4,3-A ] pyridine-3-amine 上海锐谱医药科技有限公司 2024-11-15 CN disclosed
CN-116217571-B Method for preparing medicine building block 1,2, 4-triazolo [4,3-A ] pyridine-3-amine 上海锐谱医药科技有限公司 2024-11-15 CN disclosed
CN-116217571-B Method for preparing medicine building block 1,2, 4-triazolo [4,3-A ] pyridine-3-amine 上海锐谱医药科技有限公司 2024-11-15 CN disclosed
WO-2023192817-A9 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2024-10-03 WO disclosed
US-7863291-B2 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2011-01-04 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2010-04-22 US disclosed
CN-101685733-A High-temperature thermal fuse device THERM O DISC INC 2010-03-31 CN disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed
WO-2009131926-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-29 WO disclosed
WO-2009131926-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-29 WO disclosed
WO-2009097971-A1 TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099684-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 KDM4E 3667/4885ALDH1A1 1082/4885RET 1448/4885
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES KAT6A, KAT6B, KAT2A KDM4E 227/4885ALDH1A1 1618/4885RET 3973/4885
US-12187732-B2 Inhibitors of the myst family of lysine acetyl transferases KAT6A, KAT6B, KAT2A KDM4E 227/4885ALDH1A1 1618/4885RET 3973/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 KDM4E 3667/4885ALDH1A1 1082/4885RET 1448/4885
US-20250122182-A1 MYST Inhibitors MNAT1, SUGT1, ACAT2 KDM4E 844/4885ALDH1A1 3906/4885RET 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.